Results 31 to 40 of about 5,273 (196)

A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials

open access: yesJournal of Pain Research, 2023
Anton Dormer,1 Mahesh Narayanan,1 Jerome Schentag,1 Daniel Achinko,1 Elton Norman,1 James Kerrigan,2 Gary Jay,2 William Heydorn2 1Research and Development, Pepvax, Inc, Silver Spring, MD, USA; 2Research and Development, Navintus, Inc, Princeton, NJ ...
Dormer A   +7 more
doaj  

Association of small-fiber polyneuropathy with three previously unassociated rare missense SCN9A variants

open access: yesCanadian Journal of Pain, 2020
Background: Small fiber polyneuropathy (SFN) involves ectopic firing and degeneration of small-diameter, somatic/autonomic peripheral axons. Causes include diabetes, inflammation and rare pathogenic mutations, including in SCN9-11 genes that encode small
Mary A. Kelley, Anne Louise Oaklander
doaj   +1 more source

Clinical features for diagnosis and management of patients with PRDM12 congenital insensitivity to pain. [PDF]

open access: yes, 2016
BACKGROUND: Congenital insensitivity to pain (CIP) is a rare extreme phenotype characterised by an inability to perceive pain present from birth due to lack of, or malfunction of, nociceptors.
Ahmed, Mushtaq   +7 more
core   +3 more sources

Functional confirmation that the R1488* variant in SCN9A results in complete loss-of-function of Nav1.7

open access: yesBMC Medical Genetics, 2018
Background Individuals with an extremely rare inherited condition, termed Congenital Insensitivity to Pain (CIP), do not feel pain in response to noxious stimuli.
Wen He   +10 more
doaj   +1 more source

Neuropathologic Damage Induced by Radiofrequency Ablation at Different Temperatures – An Experimental Study

open access: yesBioMedica, 2021
Background and Objective: Radiofrequency ablation (RFA) is a safe and less invasive technique that uses an electric current to damage nerve tissue to stop it from sending pain signals.
Li Su   +12 more
doaj   +1 more source

Episodic neurologic disorders: syndromes, genes, and mechanisms. [PDF]

open access: yes, 2013
Many neurologic diseases cause discrete episodic impairment in contrast with progressive deterioration. The symptoms of these episodic disorders exhibit striking variety.
Fu, Ying-Hui   +2 more
core   +2 more sources

Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 2012
Mutations in SCN9A have been reported in (1) congenital insensitivity to pain (CIP); (2) primary erythromelalgia; (3) paroxysmal extreme pain disorder; (4) febrile seizures and recently (5) small fibre sensory neuropathy. We sought to investigate for SCN9A mutations in a clinically well-characterised cohort of patients with CIP and erythromelalgia.We ...
Klein, Christopher J   +7 more
openaire   +2 more sources

Regulation of Nav1.7: A Conserved SCN9A Natural Antisense Transcript Expressed in Dorsal Root Ganglia.

open access: yesPLoS ONE, 2015
The Nav1.7 voltage-gated sodium channel, encoded by SCN9A, is critical for human pain perception yet the transcriptional and post-transcriptional mechanisms that regulate this gene are still incompletely understood.
Jennifer Koenig   +11 more
doaj   +1 more source

Genetics update: monogenetics, polygene disorders and the quest for modifying genes [PDF]

open access: yes, 2018
The genetic channelopathies are a broad collection of diseases. Many ion channel genes demonstrate wide phenotypic pleiotropy, but nonetheless concerted efforts have been made to characterise genotype-phenotype relationships.
Symonds, Joseph D., Zuberi, Sameer M.
core   +1 more source

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy [PDF]

open access: yesBMC Cancer, 2017
Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60-80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxicity remains unclear.
Sereno, María   +12 more
openaire   +6 more sources

Home - About - Disclaimer - Privacy